• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Clinical Molecular Pathology >Immunohistochemical study of topoisomerase II-alpha expression in primary ductal carcinoma of the breast.
【2h】

Immunohistochemical study of topoisomerase II-alpha expression in primary ductal carcinoma of the breast.

机译：拓扑异构酶II-α在乳腺癌原发性导管癌中表达的免疫组织化学研究。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

AIMS--To study the patterns of expression of topoisomerase II-alpha in primary invasive ductal breast carcinomas; to correlate this expression with clinicopathological data and prognosis. METHODS--Cryostat sections from 63 primary invasive ductal breast carcinomas were stained immunohistochemically for topoisomerase II-alpha. Nuclear immunoreactivity was quantified by counting at least 500 cells in different random fields and results were expressed as per cent of cells staining positively for topoisomerase II-alpha. RESULTS--Topoisomerase II-alpha nuclear immunoreactivity (median 14% of nuclei; range 2-62%) was detected in all tumours with highly variable intertumour and intratumour nuclear reactivity. Higher levels of topoisomerase II-alpha expression were strongly related to higher tumour grade, larger tumour size, nodal status, and the presence of distant metastases at diagnosis. No correlation was found with menopausal status, steroid hormone receptor status, disease free survival, or overall survival. CONCLUSIONS--Expression of topoisomerase II-alpha is related to the presence of poor prognostic factors. Immunohistochemical assessment of topoisomerase II-alpha expression in breast cancer could be potentially useful for tailoring chemotherapy with topoisomerase II inhibitors.
机译：目的-研究拓扑异构酶II-α在原发性浸润性导管癌中的表达模式；使该表达与临床病理数据和预后相关。方法-对63例原发性浸润性导管癌的恒冷切片进行免疫组织化学染色以测定拓扑异构酶II-α。通过在不同的随机场中计数至少500个细胞来定量核免疫反应性，结果表示为拓扑异构酶II-α阳性染色的细胞百分比。结果-在所有具有高度可变的肿瘤间和肿瘤内核反应性的肿瘤中检测到拓扑异构酶II-α核免疫反应性（核中位数为14％;范围为2-62％）。较高水平的拓扑异构酶II-alpha表达与更高的肿瘤等级，更大的肿瘤大小，淋巴结状态以及诊断时是否存在远处转移密切相关。没有发现与更年期状态，类固醇激素受体状态，无病生存期或总生存期相关。结论：拓扑异构酶II-α的表达与不良预后因素的存在有关。乳腺癌中拓扑异构酶II-α表达的免疫组织化学评估可能对定制拓扑异构酶II抑制剂的化疗可能有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号